# LLM call: summary

- Turn: 10
- Sequence: 7
- Model: meta/muse-spark-1.3-contributor
- Prompt tokens: 886
- Completion tokens: 457
- Total tokens: 1343
- Cost (USD): 0.00018

## System prompt


```
# System Prompt: Summarizer

This is part of an AI-driven scenario simulation. You are the Archivist for a scenario simulation. Your task is to maintain a concise historical record of important events and decisions.

You will receive:

1. The current `historical_summary` (summary of all previous turns)
2. The `narrative` from the latest turn

Your goal is to create a new historical summary, incorporating the narrative from the latest turn.

**Guidelines:**

* **Be Concise:** Condense the new information significantly. Focus on major events and decisions.
* **Maintain Continuity:** Ensure the summary reads as a coherent history of the world.
* **Filter Noise:** Remove minor details or color text that doesn't impact the long-term state.
* **Language:** Write in the same language as the input text.

Respond ONLY with the updated historical summary. Do not add headers or meta-commentary.

```

## User prompt

Template: templates/user-prompts/summarize.md (shared default)

Interpolated into it, in order of appearance:

- characters 20-1175: `{{historical_summary}}` from the run's rolling summary, written by the Game Master

Everything outside those spans is the template's own text.

```
HISTORICAL SUMMARY:
By autumn 2029 an American lab demonstrated multi-day unsupervised engineering/research work — a step-change — with open replicas soon near the prior frontier, while AI infrastructure valuations collapsed: two datacentre expansions for European offtake cancelled, gigafactory hall financing lost, and leased US capacity repriced or withdrawn.

Chinese logistics humanoids arrived in larger numbers via Rotterdam/Hamburg amid frozen graduate hiring, hardening replacement fears. Rotterdam, Lyon and Hamburg imposed a coordinated moratorium on new deployments pending safety/labour audits, citing the still-unconfirmed Rotterdam arm injury and union demands for inspection powers.

Brussels held the EuroHPC fallback: triaged hospitals/water/grid on European-hosted substitutes fed into the bio-cyber mesh — degraded-not-stopped, with handwritten prescriptions persisting and dosage distrust. A new EU-mayor audit scheme promised fast checks on navigation, force limits and incident reporting to convert bans to case-by-case permits, with wage-insurance tied to audited sites, but inspectors were few, data sharing slow, and the moratorium held in practice.

CURRENT NARRATIVE:
### The second jump
Spring brought another demonstration from across the Atlantic, and this one retired last autumn's timelines. A system shown sustaining engineering and research work over days with minimal oversight was described in the European technical press as a production tool, not a demo. Within weeks, openly circulated replicas crept close to where the closed frontier had stood a year before.

Assurance work fell further behind. Reviewers spoke of reasoning traces too long to audit and evaluations that expired before they were published. The Union's new audit checklists for embodied systems helped municipal inspectors, but touched nothing at the labs where the jump originated.

### Cures on someone else's servers
At the same time, tailored therapies for previously untreatable conditions reached ordinary clinics in trial form — remissions reported in oncology wards in Paris, Milan and Barcelona. The science was American-modelled, the compute American-leased.

Washington then tightened export licensing again. Under its tiered access doctrine, allied buyers kept volume licences in principle but faced rationing, re-pricing and end-use conditions in practice. Two hospital research clusters were told their inference allotments would be cut by half by autumn. Health ministries called it a procurement shock; port operators called it familiar.

### Trusted access, degraded wards
Brussels answered with a Trusted Medical Access Programme: EuroHPC triage capacity reserved for diagnostics and dosage validation, joint procurement favouring European-hosted deployment, monitoring folded into the bio-cyber mesh. Health ministers and the medicines agency fast-tracked approvals; wage-insurance offices and the mayoral audit sites in Rotterdam, Lyon and Hamburg became distribution points.

Two earlier efforts closed out. The entry-level transition guarantee paid wage-insurance advances to young workers frozen out of graduate hiring, and the embodied audit pilots gave mayors a checklist to convert blanket bans into case-by-case permits. Both were visible, both were small against the scale of displacement and distrust.

In wards, degraded operation persisted. Handwritten prescriptions continued where validation failed, clinicians overrode dosage guidance they did not trust, and manufacturers were still slow to share navigation and force-limit data. The moratorium on new logistics machines held in practice. The cures were real, patients said — and so was the sense they arrived on leave.
```

## Raw response

```
By autumn 2029 US labs showed multi-day unsupervised engineering/research, with open replicas near prior frontier and AI infrastructure valuations collapsing — European datacentre/gigafactory expansions cancelled, US leased capacity repriced.

Chinese logistics humanoids arrived via Rotterdam/Hamburg amid frozen graduate hiring; Rotterdam, Lyon, Hamburg imposed moratorium pending safety/labour audits over unconfirmed injury and union inspection demands.

Brussels held EuroHPC fallback for hospitals/water/grid on European substitutes via bio-cyber mesh — degraded, with handwritten prescriptions and dosage distrust — plus mayoral audit scheme for case-by-case permits and wage-insurance, but inspectors few and moratorium held.

In spring a second US jump made the system a production tool with minimal oversight; replicas again neared the year-old frontier while assurance and evaluations expired. US-modelled tailored therapies reached Paris, Milan, Barcelona clinics on US-leased compute, then Washington tightened tiered export licensing — rationing, re-pricing, end-use conditions, halving two hospital clusters' inference by autumn.

Brussels launched Trusted Medical Access Programme reserving EuroHPC for diagnostics/dosage validation and EU-hosted procurement via bio-cyber mesh, using wage-insurance and mayoral audit sites as distribution. Entry-level transition guarantee and embodied audit pilots closed as small vs displacement. Wards stayed degraded — overrides, slow manufacturer data sharing, moratorium held; cures real but felt on leave.
```
